Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.

Dendrimers have unique characteristics including monodispersity and modifiable surface functionality, along with highly defined size and structure. This makes these polymers attractive candidates as carriers in drug delivery applications. Drug delivery can be achieved by coupling a drug to polymer through one of two approaches. Hydrophobic drugs can be complexed within the hydrophobic dendrimer interior to make them water-soluble or drugs can be covalently coupled onto the surface of the dendrimer. Using both methods we compared the efficacy of generation 5 PAMAM dendrimers in the targeted drug delivery of methotrexate coupled to the polymer. The amine-terminated dendrimers bind to negatively charged membranes of cells in a non-specific manner and can cause toxicity in vitro and in vivo. To reduce toxicity and to increase aqueous solubility, modifications were made to the surface hydroxyl groups of the dendrimers. For targeted drug delivery, the dendrimer was modified to have a neutral terminal functionality for use with surface-conjugated folic acid as the targeting agent. The complexation of methotrexate within a dendrimer changes the water insoluble drug into a stable and readily water-soluble compound. When this dendrimer complexed drug, however, was placed in a solution of phosphate buffered saline, the methotrexate was immediately released and displayed diffusion characteristics identical to free methotrexate. Covalently coupled methotrexate dendrimer conjugates were stable under identical conditions in water and buffered saline. Cytotoxicity tests showed that methotrexate as the dendrimer inclusion complex had an activity identical to the free drug in vitro. In contrast, folic acid targeted dendrimer with covalently conjugated methotrexate specifically killed receptor-expressing cells by intracellular delivery of the drug through receptor-mediated endocytosis. This study demonstrates that while drug as a dendrimer inclusion complex is readily released and active in vitro, covalently conjugated drug to dendrimer is better suited for specifically targeted drug delivery.

[1]  Hisataka Kobayashi,et al.  Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. , 2003, Bioconjugate chemistry.

[2]  Anthony E. Beezer,et al.  The synthesis of water soluble dendrimers, and their application as possible drug delivery systems , 1999 .

[3]  M. Brechbiel,et al.  Specific targeting of folate–dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[4]  L R Coney,et al.  Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. , 1992, Cancer research.

[5]  K. Kono,et al.  Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. , 2000, Bioconjugate chemistry.

[6]  P C Lauterbur,et al.  Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents , 1994, Magnetic resonance in medicine.

[7]  James R. Dewald,et al.  A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .

[8]  A. Beezer,et al.  Dendrimers as potential drug carriers; encapsulation of acidic hydrophobes within water soluble PAMAM derivatives , 2003 .

[9]  D. Tomalia,et al.  Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. , 2001, Drug discovery today.

[10]  J. Reddy,et al.  Folate-targeted chemotherapy. , 2004, Advanced drug delivery reviews.

[11]  Thommey P. Thomas,et al.  Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor , 2002, Pharmaceutical Research.

[12]  William A. Goddard,et al.  Starburst Dendrimers: Molecular‐Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter , 1990 .

[13]  M. Chatterjee,et al.  Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. , 2004, Bioconjugate chemistry.

[14]  E. Meijer,et al.  Encapsulation of Guest Molecules into a Dendritic Box , 1994, Science.

[15]  Thommey P. Thomas,et al.  Targeting and inhibition of cell growth by an engineered dendritic nanodevice. , 2005, Journal of medicinal chemistry.

[16]  P. Elwood,et al.  Role of the membrane-associated folate binding protein (folate receptor) in methotrexate transport by human KB cells. , 1989, Archives of biochemistry and biophysics.

[17]  K. Kono,et al.  Water-soluble dendrimer-poly(ethylene glycol) starlike conjugates as potential drug carriers , 1999 .

[18]  James R. Baker,et al.  The Synthesis and Testing of Anti-Cancer Therapeutic Nanodevices , 2001 .

[19]  E C Wiener,et al.  Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. , 1997, Investigative radiology.

[20]  J. Ross,et al.  Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications , 1994, Cancer.

[21]  Francis C Szoka,et al.  Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. , 2002, Bioconjugate chemistry.

[22]  Sujatha Kannan,et al.  Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. , 2003, International journal of pharmaceutics.

[23]  P. Elwood,et al.  Studies of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate by cultured human KB cells. , 1985, The Journal of biological chemistry.

[24]  E. Meijer,et al.  The dendritic box, shape-selective liberation of encapsulated guests , 1995 .

[25]  N. Roehm,et al.  An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. , 1991, Journal of immunological methods.

[26]  R Langer,et al.  New methods of drug delivery. , 1990, Science.

[27]  R. Barth,et al.  Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. , 1994, Bioconjugate chemistry.

[28]  K. Kono,et al.  Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[29]  P. Low,et al.  Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. , 1993, Journal of cell science.

[30]  J. Fréchet,et al.  Designing dendrimers for drug delivery. , 1999, Pharmaceutical science & technology today.

[31]  Anil K Patri,et al.  Dendritic polymer macromolecular carriers for drug delivery. , 2002, Current opinion in chemical biology.

[32]  J. Baker,et al.  Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  F. Szoka,et al.  Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. , 2002, Bioconjugate chemistry.

[34]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Jean M. J. Fréchet,et al.  Dendrimers and other dendritic polymers , 2001 .

[36]  F. Vögtle,et al.  Dendrimers and Dendrons: Concepts, Syntheses, Applications , 2001 .

[37]  William A. Goddard,et al.  Starburst dendrimers. 5. Molecular shape control , 1989 .

[38]  P. Low,et al.  Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Brechbiel,et al.  Biodistribution of a 153Gd-Folate Dendrimer, Generation = 4, in Mice With Folate-Receptor Positive and Negative Ovarian Tumor Xenografts , 2002, Investigative radiology.

[40]  K. Kono,et al.  Design of dendritic macromolecules containing folate or methotrexate residues. , 1999, Bioconjugate chemistry.